Skip to main content

Table 4 Percentage of enriched participants for each direct comparison

From: Using the contribution matrix to evaluate complex study limitations in a network meta-analysis: a case study of bipolar maintenance pharmacotherapy review

Direct comparisons

 

PLB vs LIT

PLB vs VPA

PLB vs LTG

PLB vs IMP

PLB vs FLX

PLB LIT+IMP

PLB

vs ARP

PLB vs OLZ

PLC

vs QTP

PLB RisLAI

PLB vs PAL

LIT vs VPA

LIT vs CBZ

LIT vs LTG

LIT vs IMP

LIT vs LX

LIT vs LIT+IMP

LIT

vs LIT+VPA

LIT vs LIT+OXC

LIT vs OLZ

LIT vs QTP

VPA vs LIT+VPA

VPA vs VPA+ARP

LTG vs VPA+LTG

LTG vs ARP+LTG

IMP vs LIT+IMP

OLZ vs RisLAl

Manic

(%)

0

0

29

0

0

100

58

42

72

100

0

0

26

0

22

0

0

0

72

0

100

0

100

41

100

Depression (%)

0

0

79

0

100

0

0

0

58

0

0

0

0

76

0

100

25

0

0

0

28

0

0

100

0

46

0

  1. ARP aripiprazole, CBZ carbamazepine, FLX fluoxetine, IMP imipramine, LIT lithium, LTG lamotrigine, OLZ olanzapine, OXC oxcarbazepine, PAL paliperidone, PLB placebo, QTP quetiapine, RisLAI risperidone long-acting injection, VPA valproate